The 4 most recent market catalysts affecting $PEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 85
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
Penumbra, Inc. reported strong Q3 2026 results, with revenue up 15.6% and net income of $42.3 million. This performance indicates healthy underlying business operations, particular…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 75
Penumbra, Inc. Announces Positive Clinical Results from BOLT-DVT Trial
Penumbra, Inc. (PEN) disclosed highly positive results from its BOLT-DVT clinical trial, showcasing a 98% thrombus removal rate and a low 3.1% major adverse event rate. This is a s…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results
Penumbra, Inc. received FDA clearance for its Lightning computer assisted vacuum thrombectomy (CAVT) technology for the treatment of deep vein thrombosis (DVT). This is a significa…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 92
Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate
Penumbra's Q2 earnings report reveals a mixed performance. The substantial miss on EPS, down 23.48% year-over-year, is a significant concern for investors, indicating potential iss…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.